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Effect of Parkinson’s disease and two therapeutic interventions
on muscle activity during walking: a systematic review
Aisha Islam1, Lisa Alcock1, Kianoush Nazarpour 2,3, Lynn Rochester1,4 and Annette Pantall 1,2✉
Gait deficits are a common feature of Parkinson’s disease (PD) and predictors of future motor and cognitive impairment.
Understanding how muscle activity contributes to gait impairment and effects of therapeutic interventions on motor behaviour is
crucial for identifying potential biomarkers and developing rehabilitation strategies. This article reviews sixteen studies that
investigate the electromyographic (EMG) activity of lower limb muscles in people with PD during walking and reports on their
quality. The weight of evidence establishing differences in motor activity between people with PD and healthy older adults (HOAs)
is considered. Additionally, the effect of dopaminergic medication and deep brain stimulation (DBS) on modifying motor activity is
assessed. Results indicated greater proximal and decreased distal activity of lower limb muscles during walking in individuals with
PD compared to HOA. Dopaminergic medication was associated with increased distal lower limb muscle activity whereas
subthalamic nucleus DBS increased activity of both proximal and distal lower limb muscles. Tibialis anterior was impacted most by
the interventions. Quality of the studies was not strong, with a median score of 61%. Most studies investigated only distal muscles,
involved small sample sizes, extracted limited EMG features and lacked rigorous signal processing. Few studies related changes in
motor activity with functional gait measures. Understanding mechanisms underpinning gait impairment in PD is essential for
development of personalised rehabilitative interventions. Recommendations for future studies include greater participant numbers,
recording more functionally diverse muscles, applying multi-muscle analyses, and relating EMG to functional gait measures.
npj Parkinson’s Disease            (2020) 6:22 ; https://doi.org/10.1038/s41531-020-00119-w
INTRODUCTION
Parkinson’s disease (PD) is a multisystem neurodegenerative
disease with characteristic features present in both non-motor
and motor domains1. The non-motor clinical manifestations
include sensory impairments such as pain and tingling, depres-
sion, hyposmia and altered executive function2. The main motor
symptoms are resting tremor, bradykinesia, rigidity, postural
instability and gait disturbance3. This review is concerned with
gait dysfunction and therefore will focus on gait and related motor
symptoms.
Gait disturbance is characterised by slow shuffling steps4,
asymmetry5 and high stride-to-stride variability6,7. The increased
energy expenditure associated with dysfunctional gait makes
even a short walk a major physical effort8, thereby restricting
mobility which impacts on quality of life. Fall risk is higher in
people with PD9,10, which imposes a social and economic burden
through hospitalisation11 and subsequent health care costs12,13.
Dopaminergic treatment may reduce some abnormal gait features
such as bradykinesia and rigidity14. However, other characteristics
such as gait instability may not respond to dopaminergic therapy
in some people with PD due to various factors as outlined in the
review by Nonnekes et al.15. Long term treatment is confounded
by levodopa-induced dyskinesia, alongside fluctuations in motor
response which result in the ‘ON’ and ‘OFF’ states16. Consequently,
there is an urgent need to develop novel rehabilitative
approaches to gait dysfunction in PD.
Optimal gait is dependent upon the functional integration of
motor activity at multiple levels. At the micro level, motor units are
recruited according to the ‘size principle’ to ensure graduated
contraction and consequentially smooth movement17,18. At the
macro level, timings of muscle contractions between synergists,
antagonists and muscles acting on ipsilateral and contralateral
joints are precisely regulated. This results in an energy efficient,
forward propulsion of the individual’s centre of mass whilst
maintaining dynamic stability. Complex neuronal networks
orchestrate these constantly fluctuating muscle activation pat-
terns. Sensorimotor integration is a key component underpinning
effective locomotor neuronal networks. However, in PD, sensor-
imotor processing is impaired with resultant changes in motor
activity patterns during gait19.
Muscle activity is generally quantitatively assessed by surface or
intramuscular electromyography (EMG) which records voltage
changes in muscle fibres following stimulation by α-motoneurons.
Typical surface EMG signals in a healthy older adult (HOA) of four
bilateral lower limb muscles during walking are shown in Fig. 1.
Tibialis anterior (TA), biceps femoris (BF) and rectus femoris (RF)
are active during the initial loading phase of stance with their
corresponding contralateral muscles 180° out of phase. Lateral
gastrocnemius (LG), an ankle plantar flexor, is important later in
the stance phase for push-off of the foot. TA, an ankle dorsiflexor,
is essential for foot clearance during the swing phase. BF contracts
again towards the end of the swing phase, decelerating the
forward moving leg prior to foot touchdown. Underpinning the
timings and magnitude of EMG signals are neural networks.
Different characteristics of the EMG signal therefore offer insight
into the neural control of locomotion both at the micro and macro
level of motor control20,21. Relative timing of motor activity onset
may reveal dysfunction of sensorimotor integration. Spectral
characteristics of the EMG signal may indicate altered motor unit
recruitment strategies22,23 and presence of fatigue24. Multi-muscle
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EMG analysis and intermuscular coherence may provide informa-
tion about global control networks25,26.
Studies have found characteristic EMG gait patterns in specific
populations. Schmitz et al.27 have reported that HOAs, compared
to healthy young controls, displayed greater LG and TA activity
during stance and greater coactivation of muscles acting on the
ankle joint with larger differences observed in uniarticular muscles
such as soleus and vastus lateralis27. Another study observed
people with diabetic neuropathy to have earlier onset of activity of
soleus (SO), medial gastrocnemius (MG) and semimembranosus/
semitendinosus compared to HOA28. Alterations in muscle activity
patterns during walking have also been observed in people with
transfemoral amputation29 and individuals with cervical spondy-
lotic myelopathy compared to healthy controls30. However, it is
not clear what changes occur in muscle activity during walking in
people with PD.
Two cardinal motor features of PD likely to leave an imprint on
EMG patterns during gait are rigidity and postural instability.
Baradaran et al.31 observed that rigidity was associated with
changes in cortical/subcortical connectivity including the supple-
mentary motor area to the putamen together with increased
excitability of the motor cortex31. One possible functional
consequence of this is greater cocontraction of agonist/antagonist
muscle groups and less effective recruitment of individual
muscles. Manifestation of gait dynamic instability, defined as
instability transitioning from one gait phase to another, may be
represented by double-support time32 and greater variability of
the timing of gait such as stride time33,34. A neural correlate of gait
variability is the posterior putamen which is associated with
automatic movement and exhibits dysfunction in people with
PD35–37. Gait variability must necessarily be reflected in variability
of EMG signals. EMG parameters may provide a better indicator of
neurological dysfunction than current widely used gait
parameters.
A limitation of the common gait features extracted from body-
worn sensors such as inertial measurement units (IMUs), foot
switches, and insole pressure sensors is they lack specificity to
PD38. EMG signals differ from kinematic and kinetic features as
they are directly linked to the nervous system, via the α-
motoneurons. Several studies have reported differences in
features of EMG during non-gait motor tasks in people with PD
compared to HOAs39–41, from which mechanisms of motor control
dysfunction in PD have been inferred. Gait dysfunction is a
common motor symptom in people with PD, therefore patterns of
EMG during gait are expected to differ in people with PD
compared to controls. Gait EMG may therefore be a useful tool in
detection of PD; however, little information is available about
using gait EMG as a biomarker in PD42.
Interpretation of EMG activity is challenging, as there is high
intra-individual and inter-individual variability in EMG activity
patterns compared to kinematic and kinetic signals29. This is due
to numerous muscles performing similar actions across joints,
resulting in multiple sets of muscles able to perform a specific
motor task rather than a single set, described by Latash43 as the
‘principle of abundance’43. Further compounding the difficulty is
the variability of motor symptoms, both at the intra-individual
level and inter-individual level. Factors affecting type and severity
of motor symptoms include age, the PD phenotype, the stage of
PD, type and dosage of medication, responsiveness to medication,
and timing of assessment in relation to medication intake44,45.
Interventions targeting gait dysfunction in PD must necessarily
modify muscle activity to achieve changes in gait kinematics and
kinetics. Levodopa is the first line of treatment recommended for
targeting motor symptoms in the early stages of PD46. Deep brain
stimulation (DBS) is recommended for patients with advanced PD
whose symptoms are not alleviated by pharmaceutical therapy
(41). Krack et al.47 have reported improvements in motor function
and activities of daily living in patients with PD treated with DBS
over a five-year period47. Several studies observed DBS and
levodopa-induced comparable improvements in gait parameters
such as gait velocity48–51, step and stride length49–52, peak of
moment and power at hip and ankle49,53,54, and a reduction in
double-support time which suggests an improvement in balance
and stability52. Levodopa and DBS can be administered individu-
ally, but the combination of both treatments have demonstrated a
greater improvement in gait parameters, possibly due to working
synergistically50,52. However, there are differential effects of DBS
and levodopa on gait (for a review see ref. 55), and it is unclear
how modification of gait parameters links to the underlying
neuromuscular changes.
Understanding the neural mechanisms related to gait dysfunc-
tion is essential to improve the effectiveness of interventions, in
addition to determining what aspect of the intervention is
particularly beneficial. Crucial information regarding the mode of
action of therapeutics on neuromuscular control and correspond-
ing kinematics can be obtained by assessing whether they target
individual muscles, groups of muscles at the network level, or
affect coordination between muscles and limbs. This review will
examine the effect of dopaminergic medication and DBS on
muscle activity and function.
An essential element of this review is assessing the quality of
the studies in terms of external and internal validity. The EMG
signal is an indirect measure of muscle activity containing not only
the physiological signal but also considerable noise and artefact. It
is therefore vital that the EMG signal has been appropriately
recorded and processed according to recommended guidelines56.
This review systematically investigates studies that have
analysed EMG of lower limb muscles during walking in individuals
with PD and HOA. The first aim of this review is to critically
evaluate PD-related changes in EMG features during walking. A
further aim is to examine the effect of dopaminergic medication
and DBS on EMG activity. Understanding how muscle activity
contributes to gait impairment in PD and effects of interventions is
necessary for the development of personalised, evidence driven
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Fig. 1 Typical surface EMG signals of four bilateral lower limb
muscles recorded from a healthy older adult during walking.
Bandpass filtered unrectified EMG signals for tibialis anterior (TA),
lateral gastrocnemius (LG), biceps femoris (BF) and rectus femoris
(RF) for the right (R) and left (L) legs. Onset of the stance (St) phase
of walking for the right leg is indicated by solid vertical lines. Onset
of the swing (Sw) phase of walking for the right leg is indicated by
dashed vertical lines.
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rehabilitation techniques and to identify biomarkers which may
detect early PD57.
RESULTS
Search yield
The search strategy yielded 726 studies (Fig. 2) of which 242
duplicates were removed. Studies were screened for titles and
abstracts and 46 articles were retrieved for full-text screening.
Data were extracted from 17 papers with two papers58,59
reporting on the same study.
Quality assessment
Table 1 lists the overall scores derived from the quality appraisal
form (see Supplementary Information) which ranged from 35% to
90% with a median score of 61%. Figure 3 depicts the number of
studies scoring for each of the 20 questions. No studies scored on
Q9, which related to justification of sample size and only three
studies discussed sampling methods (Q9) or attachment of
electrodes. Fewer than half of studies clearly outlined their
hypotheses (Q7). All studies described patient characteristics (Q1),
aims (Q6), main outcomes (Q8), main findings (Q10) and (Q13)
validated outcome measures (Q20).
Study protocol
Sample size ranged from nine60,61 to forty62 for individuals with
PD and from seven63 to forty62 for healthy aged matched controls.
Ages ranged from 58.3 ± 13.5 years64 to 76 ± 6 years60 for
individuals with PD and from 58.0 ± 7.6 years64 to 74.4 ± 5.8
years65 for HOA. A greater proportion of males were assessed for
the PD groups. Eight studies did not report on gender58,59,63,66–70.
Thirteen lower limb muscles were recorded in the reviewed
studies with knee flexors and ankle plantarflexors being most
frequently recorded60–65,67,70 and only one study measuring hip
adductors65 (Fig. 4). Fourteen studies measured muscles bilater-
ally54,58,59,61–72, one study assessed only the right leg60 and one
study the most affected leg73.
The EMG recording sessions were all restricted to a gait
laboratory. Walking surfaces included level over ground walk-
ways54,62,64–71,73 of lengths between 6m62,65,67 and 25m73,
motorised treadmills60,66,73, split belt treadmills61,63,70, positive
pressure treadmill72, a treadmill simulator73 and body unloading
over a treadmill58,59 (Tables 2, 3). A range of walking speeds were
investigated including twelve studies at self-selected comfortable
walking speed54,60–62,64,65,67–71,73 (Tables 2, 3). In the remaining
studies, treadmill speeds were set at 0.25–1.0 m/s63, 0.34 ± 0.14 m/
s58,59, 0.83 m/s72 and 1.5 m/s66.
Parameters derived from EMG signals included amplitude
related measures54,58,62–66,68,70,71,73, duration of activity72, coacti-
vation indices63,67,73, multi-muscle activation61,70, variability60,69
and symmetry69. Amplitude normalisation was applied to the peak
value obtained during walking in four studies61,67,70,73 and to the
average amplitude in five studies58,59,63,69,71. One study normal-
ised to the 95th percentile of the control group54 and another to
Fig. 2 PRISMA diagram presenting overview of the search
strategy. The flow chart illustrates how publications were identified
and the resulting 17 articles extracted following screening.
Table 1. Percentage score for each study derived from quality
appraisal form (see Supplementary Information).
Studies Score (%)
Albani et al.66 35
Arias et al.67 80
Bello et al.73 85
Dietz et al.63 50
Dietz et al.58,59 60
Jenkins et al.62 65
Miller et al.69 55
Mitoma et al.65 40
Rodriguez et al.70 60
Rose et al.72 90
Caliandro et al.71 65
Cioni et al.64 55
Ferrarin et al.68 58
Pourmoghaddam et al.60 61
Rizzone et al.54 55
Roemmich et al.61 61
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Fig. 3 Quality appraisal of the 16 studies reviewed. Number of
studies from a total of 16 that scored for each of the 20 questions on
the quality appraisal form corresponding to external validity, study
information, study analysis and EMG recording and processing
techniques.
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maximum isometric voluntary contractions72. Four studies did not
report amplitude normalisation methods54,62,64,68.
The number of gait cycles included for analysis ranged from
ten58,59,64,65 to a minimum of twenty58,59,63,66. Some studies only
described the number of trials54,71 or walking time duration70.
Several did not specify the number of cycles60,62,68,69. EMG
parameters were evaluated for different phases such as the entire
gait cycle, initial/mid/terminal stance and early/late swing.
Muscle activity
Six studies compared differences in lower limb EMG activity
patterns during walking between individuals with PD in the ON
state and HOA59,62,64–66,72. Five studies reported conflicting
findings regarding TA activity during walking. Three studies
reported a reduction in MG amplitude63,65,66 during stance in
individuals with PD. Three studies found differences in proximal
muscle activity in the ON state with greater and more prolonged
activity of proximal lower limb muscles in people with PD
compared to HOA64,65,72. Two studies investigated differences in
variability of lower limb muscle activity58,69. BF, TA and MG
displayed greater variability in amplitude in individuals with PD
compared to HOA, although MG displayed lower timing varia-
bility58,69. Three studies assessed multi-muscle activity through
analysis of coactivation63,67 or muscle synergies70.
Four studies compared muscle activity during walking in the ON
state with activity during the OFF state60,61,64,71. Two studies
recorded increased TA activity during late swing/early stance in
the ON state64,71. Cioni et al.64 additionally observed increased
activity of plantarflexors during late stance64. A decrease in multi-
muscle regularity derived from recurrent quantification analysis
during the ON state was reported by Pourmoghaddam et al.60.
Roemmich et al.61 observed that composition of muscle synergies,
not the number of synergies accounting for 95% of variance,
differed between the ON and OFF states, with the synergies to
which VM and RF had higher weightings accounting for a greater
amount of variance in the OFF state compared to the ON state61.
Two studies investigated the effect of DBS on muscle activity,
with both applying DBS to the subthalamic nuclei (STN). The TA,
MG, SM and RF muscles were reported to increase activation
following DBS54,68.
Caliandro et al.71 described that individuals with PD who
displayed a reduction in TA activity during initial stance in the OFF
state had better motor function (decreased Movement Disorders
Society-Unified Parkinson’s Disease Rating Scale III (MDS-UPDRS-
III)) in the ON state, compared to individuals who demonstrated
no difference in TA activity between ON and OFF71. Arias et al.67
reported no relationship between muscle coactivation and gait
kinematics67.
DISCUSSION
To the best of our knowledge, this is the first systematic review to
report on EMG in individuals with PD during walking and the
effect of dopaminergic therapy and DBS on motor behaviour. Of
the sixteen studies identified, the majority reported differences in
EMG parameters such as the timing and amplitude of muscle
signals and muscle synergies between individuals with PD and
HOA. However, in many cases results were conflicting due in part
to differing protocols. Only six studies investigated the effect of
dopaminergic medication or DBS on EMG activity. Notably, most
studies did not relate EMG to gait or clinical measures evaluating
motor symptoms severity such as the MDS-UPDRS III, indicating a
major limitation in functional interpretation of EMG features and
understanding gait in PD. The analysis of EMG signals in isolation
without gait kinematics and kinetics or clinical measures restricts
its application. Understanding the relationship between muscle
activity and gait features will help identify which muscles and
activation patterns underpin gait impairment and provide
evidence-based support for improving the effectiveness of
rehabilitation interventions by targeting specific muscles and
muscle groups.
How does PD affect muscle activity?
Although differences were detected between individuals with PD
and HOA, there was limited consensus regarding findings,
particularly for TA, the most frequently assessed muscle. Cioni
et al.64 reported that the TA displayed similar activity patterns in
individuals with PD and HOA64. By contrast, Dietz et al.59 observed
greater TA activity and Mitoma et al.65 reported less activity in
individuals with PD59,65. Jenkins et al.62 found TA peaked later in
PD compared to healthy adults62. Albani et al.66 recorded
differences in TA in the ON state between freezers and non-
freezers with greater activity bilaterally in the swing phase in
freezers compared to HOA, whilst non-freezers showed greater
activity only in the left TA66. These findings suggest differences in
motor control of gait between people who exhibit freezing of gait
(FoG) and those who do not freeze. The contradictory findings for
TA may be accounted for in part by different processing methods
and protocols. Dietz et al.59 and Mitoma et al.65, for example, did
not normalise the amplitude of the signals59,65 which precludes
comparison of EMG amplitudes between groups (Tables 4, 5). The
Fig. 4 Proportion of studies recording lower limb muscles and
muscle groups. The chart is normalised to 100% of studies included
in this review. The outer ring contains recorded muscles: adductor
magnus (AM), biceps femoris (BF), gluteus medius (GM), lateral
gastrocnemius (LG), medial gastrocnemius (MG), semimembranosus
(SM), semitendinosus (ST), rectus femoris (RF), tibialis anterior (TA),
vastus lateralis (VL), vastus medialis (VM). The inner ring contains the
functional muscle group.
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Table 4. Methodology and signal processing techniques for non-intervention studies.
Study Lower limb muscles
Electrode placement
EMG Signal Processing EMG outcome measure Gait parameters
reported
Gait duration
analysed
Albani
et al.66
Bilateral Rectified RMS Temporal/spatial Final 20 GCs per trial
Distal: No details of filter or
method calculating RMS
reported.
Walking speed
TA, MG
Electrode placement: Normalisation
Not specified Not reported.
Arias et al.67 Bilateral Rectified Coactivation index Temporal/Spatial Minimum of 16 GCs
per subjectDistal: Bandpass: 20–450 Hz Walking speed
TA, SO Low-pass: 10 Hz Cadence
Electrode placement:
According to Cram
et al. 1998
Normalisation Step length
(a) No time normalisation
reported.
(b) Amplitude normalised
to peak baseline gait
values.
Bello et al.73 Unilateral; Bandpass: 10–500 Hz RMS Temporal/spatial Average of 3 trials
most affected leg (PD) RMS: 50 ms window Coactivation ratio of
antagonistics at ankle and
knee joints (VL-BF and TA-MG)
per gait phase.
Walking speed Third minute of
treadmill walkingright leg (HOA) Normalisation
Proximal: (a) Time normalised to GC
and divided into load,
single, pre-swing and swing
gait phases.
VL, BF (b) Amplitude normalised
to peak value during
overground walking
Distal:
TA, MG
Electrode
placement: SENIAM
Dietz et al.63 Bilateral Rectified iEMG Temporal/Spatial 20 GCs
Distal: Bandpass: 3–1000 Hz Co-activity index Stance time
TA, MG iEMG calculated for 1/20th
s of GC.
Swing time
Electrode placement: Normalisation Stance length
Not specified (a) Time normalised to
% of GC.
Stride frequency
(b) Amplitude normalised
to walking at 0.75m/s
Kinematic
Knee and ankle
joint angles
Dietz
et al.58,59
Bilateral Rectified RMS Kinematic Minimum of 10 GCs
Proximal: Bandpass: 30–300 Hz Ankle and knee
joint anglesBF, RF Averaged over 20 GCs.
Distal: RMS determined for
entire GC.
TA, MG Normalisation
Electrode placement: (a) Time normalised to
% of GC.
Not specified (b) Amplitude normalised
to normal body loading.
Electrode placement
Jenkins
et al.62
Bilateral Rectified iEMG Temporal/spatial Five walking trials
over instrumented
mat per condition
Proximal: Low-pass: 6 Hz Time to peak activity Walking speed
Quadriceps, BF EMG analysed for 4 phases:
initial stance, midstance,
terminal stance, swing
Step Length
Distal: Normalisation Step length
variability
A. Islam et al.
8
npj Parkinson’s Disease (2020)    22 Published in partnership with the Parkinson’s Foundation
walking studies were conducted on different surfaces including a
level overground walkway and motorised treadmill. Warlop et al.74
reported that treadmill walking differed in individuals with PD
compared to overground walking, therefore direct comparison
between EMG signals collected on different surfaces may give
misleading results74. Another reason for differences in TA activity
is the heterogynous nature of PD, with differences in phenotype
(tremor-dominant and postural instability and gait disturbance),
Table 4 continued
Study Lower limb muscles
Electrode placement
EMG Signal Processing EMG outcome measure Gait parameters
reported
Gait duration
analysed
TA, LG (a) Time normalised to
100% of GC.
Single-limb support
Electrode placement: (b) No amplitude
normalisation reported.Not specified
Miller et al.69 Bilateral; Rectified. Ensemble average, variability,
symmetry
Temporal/spatial
Proximal Bandpass: 30–250 Hz Stance,Step length
VL Low-pass: 10 Hz Speed
Distal Ensemble average over 6
GCs calculated.
Double/single
support phase
TA, MG Normalisation Kinematic
Electrode placement: Not
specified
(a) Time normalised to 128
point GC.
Hip, knee and ankle
joint angles
(b) Amplitude normalised
to unit intensity.
Kinetic
Ground
reaction force
CoP Displacements
Mitoma
et al.65
Bilateral Rectified iEMG Temporal/spatial 10 GCs
Proximal: Bandpass: 20–500 Hz Change in EMG Stance,Step length
AM, GM, VL, BF Integrated: 50ms between gait phases. Speed
Distal: Data were split into four
phases: 1st double support,
single support, 2nd double
support, swing.
Ratio of EMG change to joint
angle change.
Double, single
support phase
TA, gastrocnemius, SO Normalisation Kinematic
Electrode placement: Not reported. Hip, knee, ankle
joint angles
According to Knuttson &
Richards (1979)
Kinetic
Ground
reaction force
Centre of pressure.
Rodriguez
et al.70
Bilateral Demeaned, Rectified Motor modules Temporal/spatial Last 4 min of
treadmill walkingProximal: High-pass: 35 Hz Walking speed
GM, RF, VM, ST, BF Low-pass—7 Hz Kinetic
Distal: Nonnegative matrix
factorisation applied.
Sagittal hip/ knee/
ankle moment
impulsesTA, MG, SO Normalisation
Electrode placement: (a) Time normalised to
100% of GC.
Not specified (b) Amplitude normalised
to peak trial values.
Rose et al.72 Bilateral RMS: 21ms window RMS: 21ms window Kinetic 20 s of walking
Proximal: Normalisation Normalisation Knee joint torque
VL, VM, SM, BF (a) No time normalisation
reported.
(a) No time normalisation
reported.
Ground
reaction force
Electrode placement:
According to Perotto
et al. 2005.
(b) Amplitude normalised
to maximum value during
isometric maximum
voluntary contractions
(b) Amplitude normalised to
maximum value during
isometric maximum voluntary
contractions
CC correlation coefficient, COV coefficient of variation, DC direct current, GC Gait cycle, HOA healthy older adult, iEMG integrated EMG, RMS root mean square,
ROM range of motion, RQA recurrence quantification analysis, SENIAM, surface EMG for non-invasive assessment of muscles, SR sampling rate, %DET percent
determinism. Muscle: AM adductor magnus, BF biceps femoris, GM gluteus medius, LG lateral gastrocnemius, MG medial gastrocnemius, PL peroneus longus, SM
semimembranosus, ST semitendinosus RA, RF rectus femoris, TA tibialis anterior, TFL tensor fascia latae, VL vastus lateralis, VM vastus medialis.
A. Islam et al.
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Table 5. Methodology and signal processing techniques for intervention studies.
Study Lower limb muscles
Electrode placement
EMG Signal Processing EMG outcome
measure
Gait parameters
reported
Gait duration
analysed
Caliandro et al.71 Bilateral Rectified Peak RMS for TA at Temporal/spatial Two trials of 10 m for
each sessionDistal: High-pass: 50 Hz Late swing to
early stance
Walking speed
TA, MG Low-pass: 7.5 Hz
Electrode placement:
According to Rainoldi
et al. 2004
RMS: 50 ms window
Normalisation
Not reported.
Cioni et al.64 Bilateral Rectified iEMG Temporal/Spatial Minimum of 10 GCs
Proximal: Time averaged at 50 Hz Walking speed
Quadriceps, hamstrings Stance (% GC)
Distal: Normalisation Stride length
TA, triceps surae (a) Time normalised to 100%
of GC in 2% increments.
Cadence
Electrode placement: (b) No amplitude
normalisation reported.
Kinematic
Not specified hip, knee, ankle
joint angles
Ferrarin et al.68 Bilateral; Rectified. RMS Temporal/Spatial
Proximal Bandpass: 10–200 Hz Speed
RF, SM High-pass: 50 Hz Stride length
Distal Low-pass: 7 Hz Cadence
TA, MG RMS calculated for: 1st
double support, early single
support, late single support,
2nd double support, early
swing, late swing.
Velocity
Electrode
placement: SENIAM
Normalisation Stance
(a) Time normalised to
100% of GC.
Kinematic
(b) No amplitude
normalisation reported.
Hip, knee and
ankle ROM
Kinetic
Peak joint moments
and powers at the
hip, knee and ankle
Pourmoghaddam
et al.60
Unilateral: right leg Bandpass: 20–460 Hz. Index based on
algorithm
composed of
products of %DET.
Temporal/Spatial Up to 180 s
overground walking
before and after
taking medication.
Proximal: RQA applied. %DET
calculated for individual
muscles.
Walking speed
RF, VM, BF ‘Synergos’ index determined
using algorithm involving
products of %DET.
Distal: Normalisation
TA, LG, SO None reported
Electrode placement:
Not specified
Roemmich et al.61 Bilateral; Demeaned, rectified. Motor modules Temporal/Spatial 10–20 GCs before
and after medicationProximal High-pass: 35 Hz Velocity
GM, RF, VM, SM, BF Low-pass: 7 Hz Kinematic
Distal Nonnegative matrix
factorisation applied.
Stride length
TA, MG, SO Normalisation Step length
Electrode placement: Not
specified
(a) Time normalised to
100% of GC.
Stride time
(b) Amplitude normalised to
peak trial values.
Step time
Rizzone et al.54 Bilateral Rectified RMS Temporal/Spatial Eight trials in each
conditionProximal: Bandpass: 10–200 Hz. Speed,Stride length
A. Islam et al.
10
npj Parkinson’s Disease (2020)    22 Published in partnership with the Parkinson’s Foundation
disease duration, symptom severity and features such as FoG.
Functionally, decreased TA activity reduces foot clearance75 and
alters foot contact patterns which may influence fall risk. A shorter
duration of TA muscle activity occurs prematurely in individuals
with PD prior to freezing76.
Studies investigating the activity of MG muscle in individuals
provided more conclusive results, with the majority reporting
reduced activity in the PD group compared to HOA. As the MG
muscle is important for forward propulsion of the body and
vertical support77, a decrease in activity may result in reduced gait
speed and loss of postural balance along the vertical axis. Three
studies reported prolonged increased activity of knee flexors and
extensors64,65,72 in individuals with PD. Biomechanically, the
enhanced proximal muscle activity may compensate for
the reduced function of distal muscles. Greater contraction of
the quadriceps during the stance phase will increase extension of
the knee, leading to greater stability in this joint during single
stance which may compensate for reduced stability at the ankle
joint. Greater activity of hamstrings during swing will increase hip
extension and knee flexion and may replace some of the foot
placement and initial loading role of the distal muscles acting on
the ankle joint. Increased muscle activity entails a larger metabolic
demand which may limit walking speed and mobility78. Differ-
ential compensatory changes in lower limb muscles during
walking have been observed in other neurological pathologies
such as post-polio syndrome and stroke79,80.
Other EMG measures determined in the reviewed articles
included variability, coactivation, muscle synergies and asymme-
try. Two studies assessed variability of EMG amplitude and
reported greater variability of EMG for proximal and distal
muscles58,69. Increased EMG variability suggests decreased auto-
maticity of locomotor control in PD resulting from the dysfunc-
tional putamen81. Clinically, greater gait variability is associated
with higher falls risk in individuals with PD and HOA33. However,
the relationship between variability and stability is complicated
with a certain level of variability essential to enable adaption to
perturbations82. There was conflicting evidence regarding
changes in coactivation of agonists and antagonists in lower limb
muscle pairs during walking in individuals with PD. Dietz et al.63
observed increased coactivation of TA and MG in people with PD
during treadmill walking compared to HOA whereas Arias et al.67
reported no difference in coactivation of TA and SO when walking
overground63,67. A motorised treadmill can act as an external cue
resulting in reduced gait variability and altered coordination of
muscles74. Only one study assessed muscle synergies and
observed fewer muscle synergies accounting for 95% of variance,
altered temporal profiles and a higher percentage of variability
accounted for by MG, SM and BF in the PD group compared to
HOA70. A reduction in muscle synergies suggests a simpler,
possibly less robust, control system83. Miller et al.69 reported
higher asymmetry in TA and MG activity in PD compared to
HOA69. Motor and gait asymmetry are early features of PD84–86.
Greater asymmetry is associated with the reduced integrity of
callosal sensorimotor regions87 and impairment in sensorimotor
integration, in addition to an increased risk of falls88.
How is muscle activity modified by interventions?
Altered contraction of individual muscles and coordination of
activity between muscles underpin gait impairment in PD.
Interventions targeting gait dysfunction must therefore modify
activity of individual muscles and activation patterns. Evidence
from the reviewed studies indicate that dopaminergic medica-
tion64,71 and STN-DBS54,68 increase the activity of distal lower limb
muscles, particularly of the TA muscle. The TA has been reported
to have greater projections from the cortex to its motoneurons
compared to other lower limb muscles which may account for this
muscle being targeted more89. The effect of enhanced muscle
contraction, providing there is no increase in the antagonist
muscle, is to increase the forces acting about a joint (joint
moments). The functional consequence of this is increased
angular velocity resulting in increased gait velocity which has
been observed to occur following dopaminergic medication and
STN-DBS, achieved mainly through longer step length90,91. In
individuals with PD, the plantarflexors are impacted more than the
dorsiflexors and there is no evidence that the dorsiflexors are
weaker in individuals with PD compared to HOA. Increasing
disproportionately the activity of the dorsiflexors relative to the
plantarflexors will produce an imbalance in forces around the
ankle joint with possible associated instability. The effect of STN-
DBS on muscle function differs from that of dopaminergic
medication as it increases activity of both proximal and distal
lower limb muscles. Individuals with PD generally exhibit
decreased activity of distal muscles and greater activity of
proximal lower limb muscles as outlined in the previous section.
A further increase in proximal lower limb muscle due to STN-DBS,
may result in imbalance of forces across and between joints and
contribute to aggravation of FoG and postural instability which
has been reported following STN-DBS92.
Only one study assessed variability of gait EMG following
dopaminergic medication. Pourmoghaddam et al.60 observed
decreased multi-muscle regularity, determined through nonlinear
analysis methods, during the ON state60. This implies increased
variability of EMG patterns which could contribute to postural
stability not being well controlled by dopaminergic medication,
Table 5 continued
Study Lower limb muscles
Electrode placement
EMG Signal Processing EMG outcome
measure
Gait parameters
reported
Gait duration
analysed
RF, SM High-pass: 50 Hz Cadence
Distal: Low-pass: 7.5 Hz Stance time
TA, MG RMS calculated for 4t gait
phases:
Kinematic
Electrode placement: Normalisation Hip, knee, ankle ROM
Not specified (a) Time normalised as % of
stride duration.
Kinetic
(b) No amplitude
normalisation reported.
Hip, knee and ankle
joint power and
moments
CC correlation coefficient, COV coefficient of variation, DC direct current, GC gait cycle, HOA healthy older adult, iEMG integrated EMG, RMS root mean square,
ROM range of motion, RQA recurrence quantification analysis, SENIAM surface EMG for non-invasive assessment of muscles, SR sampling rate, %DET percent
determinism. Muscle: AM adductor magnus, BF biceps femoris, GM gluteus medius, LG lateral gastrocnemius, MG medial gastrocnemius, PL peroneus longus,
SM semimembranosus, ST semitendinosus RA, RF rectus femoris, TA tibialis anterior, TFL tensor fascia latae, VL vastus lateralis, VM vastus medialis.
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although more evidence is needed in support91. Two studies have
reported that step time variability decreased with dopaminergic
medication and Gilat et al.93 observed this variability was
associated with altered striatal, limbic and cerebellar activity93,94.
Dopaminergic medication and STN-DBS modulate activity of
similar brain structures and networks with some differences
reported. Evidence indicates that dopaminergic medication and
STN-DBS suppress the primary motor cortex (M1)-STN beta band
(13–35 Hz) coherence95–98. Studies investigating cyclical move-
ments of upper and lower limbs have found cortico-muscular beta
coherence to be enhanced following dopaminergic medica-
tion99,100. STN-DBS has similarly been observed to increase
cortico-muscular beta coherence in hand tremor101. Increased
cortico-muscular beta band coherence has been linked with
greater muscle activity102. Mueller et al.103 additionally reported
dopaminergic medication increased connectiveness between the
putamen and both the cerebellum and brainstem, with high
connectivity correlated with a better motor score (UPDRS-III)103.
STN-DBS has also been found to increase activity of motor cortical
regions during movement and decrease activity during rest, with
lower cortical activity during rest associated with clinical
improvement98. These differences in brain targets may account
for the varying effects dopaminergic medication and STN-DBS
have on gait. In postural studies, dissimilar outcomes have also
been reported, with dopaminergic medication increasing postural
sway area whereas STN-DBS reduced postural sway area104.
What is the quality of the reviewed studies?
Overall, quality scores were mediocre for both non-intervention
and intervention studies. The main points that studies scored low
on were sample size justification, electrode placement procedures
and signal processing techniques. Individuals with PD exhibit
great heterogeneity and generally high inter- and intra- subject
gait EMG variability105 necessitating greater sample sizes than for
HOA. However, the median sample size was only twenty-two and
no study in this review performed power analysis to justify their
selection of participant number. Most studies included a greater
proportion of males, reflecting the gender bias in PD although
some studies did not specify gender. Gender differences in muscle
activity during walking have previously been reported106,107
indicating it is an important factor. Only four studies determined
electrode location using validated guidelines such as the SENIAM
guidelines108. Identification of the optimal electrode site helps
ensure the signals with higher signal to noise ratio are recorded
from the selected muscle with minimal cross-talk from adjacent
muscles109.
Over half of the studies did not report any signal normalisation
methods59–61,63,65,66,69–71. Such normalisation is essential to allow
comparisons of EMG between muscles, sessions and participants
as factors such as thickness of adipose tissue, presence of oedema
and number and orientation of muscle fibres will modify
amplitude110,111. Excluding normalisation can invalidate subse-
quent results.
For the intervention specific studies, all studies excluded reports
of adverse events and two studies did not state whether the
researchers were blinded from measuring the main outcomes54,68.
Reporting of adverse events is crucial for ensuring participant safety
and determining potential confounding factors which may influence
results interpretation and subsequent intervention development.
Limitations of reviewed studies
A small selection of superficial lower limb muscles was assessed
during walking in individuals with PD with certain muscle groups
studied less. Information about the contribution of muscles to
movement is necessary for understanding compensatory mechan-
isms resulting in impaired gait and dynamic postural control and
for developing interventions. Only one study recorded the hip
adductors, a muscle group with a cross-sectional area (CSA), which
relates to muscle force, comparable to the CSA of the quadriceps
group, and almost three times greater than the CSA of the
hamstrings112. This creates a vacuum in our knowledge of motor
activity during walking in PD particularly given that mediolateral
sway and instability are greater in individuals with PD113. The
reviewed studies reported group differences in a wide range of
EMG parameters including temporal information (muscle onset/
offset), amplitude (root mean square, integrated EMG, mean
amplitude of EMG), coactivation indices, synergies, symmetry/
variability indices and nonlinear indices. However, spectral
characteristics of the EMG signals and intermuscular coherence,
which may provide information about motor unit recruitment and
neuronal networks controlling muscle activity, were not analysed.
All studies were conducted in a gait laboratory with participants
being closely observed whilst walking under constrained condi-
tions. Spatio-temporal measures of gait and by implication muscle
activity are modified when gait is observed overtly rather than
covertly114. Only single-task walking was generally assessed.
However, real-world walking involves additional activities such
as walking and turning, varying walking speeds, completing
complex visuomotor tasks and talking115,116. As an individual’s
EMG profile will vary from day to day117, recording over multiple
days and over a longer time period could permit a more accurate
appraisal of motor activity to be made and also determine how
motor activity changes over time and with disease progression.
Repeat measurements are particularly important for individuals
with PD as they will exhibit considerable fluctuation in gait
depending on their medication regimes.
Thus, the current information regarding EMG activity during gait
in PD is restricted in its ability to reflect the complexity of real-life
walking and the capacity of the nervous system to integrate
multiple neural networks to ensure safe efficient walking and
facilitate gait adaptations in response to varying environmental
demands. Measurement of muscle activity patterns during real-
world gait over longer time periods would capture the specific
motor control strategies used under these conditions that would
otherwise be confounded by testing in a controlled environment.
There are, however, challenges with monitoring free-living EMG,
given the high sampling rate needed and low signal to noise ratio
compared to wearable sensors such as accelerometers.
Limitations
This systematic review carries the usual limitations regarding
restrictions imposed by the nature of literature selection. Only
English-language journals were included. Studies involving gait
initiation, freezing episodes, running and upper limb muscles/
tasks were excluded as inclusion criteria stipulated only walking
tasks. Further studies are required to understand task-based
differences in EMG activity between PD and controls as at present
there is insufficient evidence in the literature to conduct this type
of review.
Recommendations
This review has raised many issues regarding the limitations
surrounding our current knowledge of motor activity during
walking in individuals with PD. Recommendations for future
studies are provided below and divided into points relating to
study protocol and data processing.
Protocol considerations for EMG
● Real-world walking. Investigating gait during real-world activity
is desirable to understand motor strategies in a natural
A. Islam et al.
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environment although current technological limitations make
long term recordings challenging.
● Sample size. Greater numbers of participants and more stride
cycles are necessary.
● Muscle selection. Muscles representing all major muscle groups
acting on the ankle, knee and hip joints in the sagittal and
coronal planes should ideally be recorded to permit analyses of
multi-muscle activation patterns and underlying neural control
systems to be undertaken.
● Electrode placement. A clear statement must be included
regarding methods used to identify electrode placement and
established guidelines followed.
● Longitudinal studies. This will inform us how motor patterns
change with age and disease progression and help establish
EMG characteristics as biomarkers.
● Additional gait and cortical parameters. Parameters such as
joint kinematics and kinetics as well as cortical activity
measured with mobile, wireless systems such as functional
near infrared spectroscopy or electroencephalography will
enable us to relate EMG to gait impairment and cortical
processes.
Data analytical considerations for EMG
● Filtering and normalisation. Appropriate filtering techniques
must be performed to ensure signals are physiological and not
convoluted by noise. Normalisation techniques must be
applied to each muscle for each individual to allow
comparisons.
● Parameter selection. Parameters should be selected that
reflect underlying neural control systems, physiology and gait
dysfunction. Spectral analysis, nonlinear analysis of variability,
and factor analysis methods, such as nonnegative matrix
factorisation, may indicate neurophysiological mechanisms.
Relating EMG outcome to specific gait functions such as
loading, push-off and swing is important for identifying
targets for gait rehabilitation in PD.
CONCLUSION
Results from this review indicate individuals with PD have
decreased activity of distal lower limb muscles, specifically
plantarflexors, and increased activity of proximal lower limb
muscles during walking compared to HOA. Variability of EMG of
lower limb muscles during walking is increased in individuals with
PD. Dopaminergic medication enhances activity of distal muscles
and STN-DBS increases both proximal and distal muscle activity
during walking. The effect of further increase in proximal muscle
contraction may contribute to FoG and gait instability associated
with STN-DBS. There is insufficient evidence to state how changes
in muscle activation patterns directly relate to altered tempor-
ospatial gait parameters.
The findings from this review highlight the paucity of
information regarding how muscles contract during walking in
people with PD and how this activity relates to gait impairment.
This lack of information about muscle activity is in marked
contrast to the wealth of knowledge we have concerning spatio-
temporal features of gait or neurodegenerative changes in the
brain, requiring invasive techniques. Consequently, although gait
impairment is common in PD, we cannot identify which muscles
are responsible for slower walking speed or shorter steps, or why
falls occur more commonly.
It is not feasible, due to insufficient data, to differentiate
individuals with PD from HOA through analysis of muscle activity.
Further studies must be undertaken, to enable gait EMG to be
employed as a biomarker of PD and to generate personalised
rehabilitation techniques targeting dysfunctional muscles. The
future challenge is to develop a multi-centre project involving a
large cohort of individuals with PD and HOA, which investigates a
comprehensive set of muscles and extracts a range of parameters
from the EMG over an extended time-period in different settings.
METHODS
Search strategy
A literature search was performed in December 2019 to identify relevant
articles in the following databases by one author (AI): MEDLINE
(1946–2019), Embase (1974–2019), Scopus and Web of Knowledge
(Table 6). The search extended back to 1946 to include articles published
in the 1960s when surface EMG was first introduced, and patients were
first prescribed levodopa.
Four search fields were selected linked with the conjunction ‘’OR”. MESH
headings were used for Medline and Embase. Synonyms for each key term
were applied. The first search field comprised the measurement technique
of interest (EMG) with surface and wire/needle EMG included. The second
search field focused on Parkinson’s only, excluding atypical PD and other
parkinsonian disorders. The third field consisted of synonyms for walking
tasks and gait characteristics. The final search field contained descriptors
for the data analysis used (e.g. muscle activation patterns, muscle
synergies). The searches from all four databases were combined into a
citation manager with duplicates removed. Three authors (AI, AP, LA)
screened suitable titles and abstracts. Full text review was performed if the
suitability of a paper for inclusion was unclear. Reference lists were
manually scanned during full text review to identify relevant articles.
Inclusion and exclusion criteria
Articles recording the EMG signal in individuals with PD during forward,
straight line walking were included. Studies which focused on specific
phases of walking such as turning, gait initiation and termination or a
special type of walk such as backward walking or walking in the Timed Up
and Go (TUG) test were excluded. Studies that only analysed static standing,
posture and tremor or specific gait events observed in PD such as freezing
of gait were excluded. Studies involving groups with pathologies outside of
PD were excluded. Dopaminergic studies (ON/OFF) and DBS studies were
Table 6. Search fields with their corresponding search term used.
Measurement
technique
Population Gait Data analysis
Electromyography Parkinson’s
Disease
Walk* Muscle synerg*
Surface EMG Gait Muscle activit*
Invasive EMG Stance Muscle patterns
Step* Coherence
Stride Coactivation
Swing Cocontraction
Speed
‘Double limb’
Dorsiflex*
Plantarflex*
Locomot*
Ambul*
Pace
Rhythm
Tread
Asymmetr*
Symmetr*
Variability
Frequency
Velocity
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only included when the EMG signal during a walking task was reported.
Only articles written in English were considered. Reviews, abstracts, cohort
studies, case studies, editorials, commentaries, discussion papers, con-
ference proceedings and studies lacking full text were excluded. Eligibility
and inclusion were determined by three reviewers (AI, AP, LA).
Discrepancies were resolved through discussion resulting in a unanimous
decision or a majority consensus.
Data extraction
Data extraction forms were created for each study and data were extracted
independently by the reviewers (AI, AP, LA). Data extracted includes
author, publication date, study aims, participant characteristics, medication
state, walking surface, walking task and the key findings from the studies,
muscles assessed, electrode placement, signal-processing techniques, EMG
outcome measures, gait parameters and the gait duration/length analysed.
Data were synthesised and formatted into tables. Tables 2 and 3 list aims,
participant characteristics, medication state, walking surface, walking task
and the key findings from non-intervention and intervention studies,
respectively. Tables 4 and 5 contain EMG related descriptors including
muscles assessed, electrode placement, signal-processing techniques, EMG
outcome measures, gait parameters and the gait duration/length analysed
for non-intervention and intervention studies, respectively.
Quality assessment
A customised quality appraisal form (see Supplementary Information)
based on sources addressing the themes in this review was developed. The
components of the quality assessment considered both internal and
external validity of studies by integrating generic principles of systematic
reviews118, intervention studies119,120, reviews assessing EMG and
gait121,122 and standardised reporting of EMG data123,124.
External validity considers the applicability and generalisability of the
study in other settings and contexts. Themes of external validity included
participant characteristics and selection methods. Internal validity refers to
the extent of no bias in a study validity and other aspects of research
design (e.g. randomisation, blinding, study protocol consistency), and the
processing of EMG data. The reviewed studies were divided into two
groups: intervention and non-intervention. An additional subset of
questions was included to assess the quality of intervention studies only.
We defined quality of studies as low (<50%), medium (50–69%) and high
(≥70%).
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